1-20 of 26
David M. Hyman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Michele L. LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bedard, Funda Meric-Bernstam, Rinaa S. Punglia, Deborah Schrag, Eva M. Lepisto, Fabrice Andre, Lillian Smyth, Semih Dogan, Celeste Yu, Chetna Wathoo, Mia Levy, Lisa D. Eli, Feng Xu, Grace Mann, Alshad S. Lalani, Fei Ye, Christine M. Micheel, Monica Arnedos
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2118–2130.
https://doi.org/10.1158/1078-0432.CCR-21-0885
Published: 13 May 2022
View article titled, Natural History and Characteristics of <em>ERBB2</em>-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Open the PDF for Natural History and Characteristics of <em>ERBB2</em>-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE in another window
Includes: Supplementary data
Journal Articles

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 3845–3853.
https://doi.org/10.1158/1078-0432.CCR-20-4548
Published: 15 July 2021
View article titled, Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Open the PDF for Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations in another window
Includes: Supplementary data
Journal Articles

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Philippe L. Bedard, Jasgit C. Sachdev, Lara Dunn, Helen Won, John Bond, Surai Jones, Heidi M. Savage, Maurizio Scaltriti, Timothy R. Wilson, Michael C. Wei, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 447–459.
https://doi.org/10.1158/1078-0432.CCR-20-2657
Published: 19 January 2021
View article titled, Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers
Open the PDF for Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3947–3957.
https://doi.org/10.1158/1078-0432.CCR-19-3953
Published: 03 August 2020
View article titled, Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Open the PDF for Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing

Martee L. Hensley, Shweta S. Chavan, David B. Solit, Rajmohan Murali, Robert Soslow, Sarah Chiang, Achim A. Jungbluth, Chaitanya Bandlamudi, Preethi Srinivasan, William D. Tap, Evan Rosenbaum, Barry S. Taylor, Mark T.A. Donoghue, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3881–3888.
https://doi.org/10.1158/1078-0432.CCR-19-3959
Published: 15 July 2020
View article titled, Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
Open the PDF for Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing in another window
Includes: Supplementary data
Journal Articles

Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer

Yonina R. Murciano-Goroff, Emily S. Lebow, Hai-Yan Tu, Mark Li, Lee P. Lim, Kathryn C. Arbour, William Travis, David B. Solit, Marc Ladanyi, David R. Jones, Charles M. Rudin, Andres Martinez, Mackenzie L. Myers, Alexander Makhnin, Pedram Razavi, Michael D. Offin, James W. Isbell, Gregory J. Riely, David M. Hyman, Piro Lito, Bob T. Li
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): 12.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-12
Published: 15 June 2020
View article titled, Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer
Journal Articles

Abstract 16: Landscape and outcome of TRK fusion-positive Cancers

Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): 16.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-16
Published: 15 June 2020
View article titled, Abstract 16: Landscape and outcome of TRK fusion-positive Cancers
Journal Articles

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1624–1632.
https://doi.org/10.1158/1078-0432.CCR-19-3165
Published: 01 April 2020
View article titled, TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Open the PDF for TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations in another window
Includes: Supplementary data
Journal Articles

Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib

Gary A. Ulaner, Cristina Saura, Sarina A. Piha-Paul, Ingrid Mayer, David Quinn, Komal Jhaveri, Ben Stone, Seta Shahin, Grace Mann, Melanie Dujka, Richard Bryce, Funda Meric-Bernstam, David B. Solit, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7381–7387.
https://doi.org/10.1158/1078-0432.CCR-19-1658
Published: 13 December 2019
View article titled, Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib
Open the PDF for Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib in another window
Journal Articles

Abstract AP27: A PHASE 2 STUDY OF TPIV200/HUFR-1 (A MULTI-EPITOPE FOLATE RECEPTOR ALPHA VACCINE) IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER

Dmitriy Zamarin, Oladapo Yeku, Rosin E. O'Cearbhaill, Karen A. Cadoo, Jacqueline Gallagher, Sara Kravetz, Autumn McDonnell, Tiffany Troso-Sandoval, Paul Sabbatini, Stuart Lichtman, William Tew, Vicky Makker, Rachel N. Grisham, David M. Hyman, Carol Aghajanian, Jason Konner
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): AP27.
https://doi.org/10.1158/1557-3265.OVCASYMP18-AP27
Published: 15 November 2019
View article titled, Abstract AP27: A PHASE 2 STUDY OF TPIV200/HUFR-1 (A MULTI-EPITOPE FOLATE RECEPTOR ALPHA VACCINE) IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER
Journal Articles

Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas

Philip Jonsson, Andrew L. Lin, Robert J. Young, Natalie M. DiStefano, David M. Hyman, Bob T. Li, Michael F. Berger, Ahmet Zehir, Marc Ladanyi, David B. Solit, Angela G. Arnold, Zsofia K. Stadler, Diana Mandelker, Michael E. Goldberg, Juliann Chmielecki, Maryam Pourmaleki, Shahiba Q. Ogilvie, Shweta S. Chavan, Andrew T. McKeown, Malbora Manne, Allison Hyde, Kathryn Beal, T. Jonathan Yang, Craig P. Nolan, Elena Pentsova, Antonio Omuro, Igor T. Gavrilovic, Thomas J. Kaley, Eli L. Diamond, Jacqueline B. Stone, Christian Grommes, Adrienne Boire, Mariza Daras, Anna F. Piotrowski, Alexandra M. Miller, Philip H. Gutin, Timothy A. Chan, Viviane S. Tabar, Cameron W. Brennan, Marc Rosenblum, Lisa M. DeAngelis, Ingo K. Mellinghoff, Barry S. Taylor
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (18): 5537–5547.
https://doi.org/10.1158/1078-0432.CCR-19-0032
Published: 13 September 2019
View article titled, Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
Open the PDF for Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

Jessica J. Tao, Nicholas A. Cangemi, Vicky Makker, Karen A. Cadoo, Joyce F. Liu, Drew W. Rasco, Willis H. Navarro, Christopher M. Haqq, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5458–5465.
https://doi.org/10.1158/1078-0432.CCR-19-1065
Published: 13 September 2019
View article titled, First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny, Alison M. Schram, Charles M. Rudin, David M. Hyman, Maria E. Arcila, Michael F. Berger, Ahmet Zehir, Mark G. Kris, Alexander Drilon, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4712–4722.
https://doi.org/10.1158/1078-0432.CCR-19-0225
Published: 01 August 2019
View article titled, High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Open the PDF for High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden in another window
Includes: Supplementary data
Journal Articles

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

James J. Harding, Subhiksha Nandakumar, Joshua Armenia, Danny N. Khalil, Melanie Albano, Michele Ly, Jinru Shia, Jaclyn F. Hechtman, Ritika Kundra, Imane El Dika, Richard K. Do, Yichao Sun, T. Peter Kingham, Michael I. D'Angelica, Michael F. Berger, David M. Hyman, William Jarnagin, David S. Klimstra, Yelena Y. Janjigian, David B. Solit, Nikolaus Schultz, Ghassan K. Abou-Alfa
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2116–2126.
https://doi.org/10.1158/1078-0432.CCR-18-2293
Published: 01 April 2019
View article titled, Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
Open the PDF for Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies in another window
Includes: Supplementary data
Journal Articles

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

Tara E. Soumerai, Mark T.A. Donoghue, Chaitanya Bandlamudi, Preethi Srinivasan, Matthew T. Chang, Dmitriy Zamarin, Karen A. Cadoo, Rachel N. Grisham, Roisin E. O'Cearbhaill, William P. Tew, Jason A. Konner, Martee L. Hensley, Vicky Makker, Paul Sabbatini, David R. Spriggs, Tiffany A. Troso-Sandoval, Alexandra Snyder Charen, Claire Friedman, Mila Gorsky, Sarah J. Schweber, Sumit Middha, Rajmohan Murali, Sarah Chiang, Kay J. Park, Robert A. Soslow, Marc Ladanyi, Bob T. Li, Jennifer Mueller, Britta Weigelt, Ahmet Zehir, Michael F. Berger, Nadeem R. Abu-Rustum, Carol Aghajanian, Deborah F. DeLair, David B. Solit, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5939–5947.
https://doi.org/10.1158/1078-0432.CCR-18-0412
Published: 03 December 2018
View article titled, Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Open the PDF for Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma

Lee S. Gottesdiener, Shannon O'Connor, Klaus J. Busam, Helen Won, David B. Solit, David M. Hyman, Alexander N. Shoushtari
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5815–5819.
https://doi.org/10.1158/1078-0432.CCR-18-1397
Published: 03 December 2018
View article titled, Rates of <em>ERBB2</em> Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an <em>ERBB2</em>-Amplified Acral Melanoma
Open the PDF for Rates of <em>ERBB2</em> Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an <em>ERBB2</em>-Amplified Acral Melanoma in another window
Journal Articles

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

Maeve A. Lowery, Ryan Ptashkin, Emmet Jordan, Michael F. Berger, Ahmet Zehir, Marinela Capanu, Nancy E. Kemeny, Eileen M. O'Reilly, Imane El-Dika, William R. Jarnagin, James J. Harding, Michael I. D'Angelica, Andrea Cercek, Jaclyn F. Hechtman, David B. Solit, Nikolaus Schultz, David M. Hyman, David S. Klimstra, Leonard B. Saltz, Ghassan K. Abou-Alfa
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17): 4154–4161.
https://doi.org/10.1158/1078-0432.CCR-18-0078
Published: 04 September 2018
View article titled, Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Open the PDF for Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martinez, Enaksha Wickremsinhe, Aaron Fink, Volker Wacheck, Kathleen N. Moore
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3253–3262.
https://doi.org/10.1158/1078-0432.CCR-17-3421
Published: 15 July 2018
View article titled, A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Open the PDF for A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

David M. Hyman, Naiyer Rizvi, Ronald Natale, Deborah K. Armstrong, Michael Birrer, Lawrence Recht, Efrat Dotan, Vicky Makker, Thomas Kaley, Denison Kuruvilla, Matthew Gribbin, Jennifer McDevitt, Dominic W. Lai, Mohammed Dar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2749–2757.
https://doi.org/10.1158/1078-0432.CCR-17-1775
Published: 14 June 2018
View article titled, Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
Open the PDF for Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, Lei Tian, Jane L. Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano G. Martelotto, Charlotte K.Y. Ng, Raymond S. Lim, Pier Selenica, Salvatore Piscuoglio, Carol Aghajanian, Larry Norton, Rajmohan Murali, David M. Hyman, Laetitia Borsu, Maria E. Arcila, Jason Konner, Jorge S. Reis-Filho, Roger A. Greenberg, Mark E. Robson, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (21): 6708–6720.
https://doi.org/10.1158/1078-0432.CCR-17-0544
Published: 31 October 2017
View article titled, Diverse <em>BRCA1</em> and <em>BRCA2</em> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Open the PDF for Diverse <em>BRCA1</em> and <em>BRCA2</em> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer in another window
Includes: Supplementary data